Reach Us +441414719275
Stem Cell Therapy For The Treatment Of Severe Tissue Damage After Radiation Exposure | 94755
ISSN: 2157-7552

Journal of Tissue Science & Engineering
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Stem cell therapy for the treatment of severe tissue damage after radiation exposure

13th International Conference on Tissue Engineering & Regenerative Medicine

Alain Chapel

Institute of Radiological Protection and Nuclear Safety, FranceUniversity Pierre et Marie Curie, France

ScientificTracks Abstracts: J Tissue Sci Eng

DOI: 10.4172/2157-7552-C2-048

The late adverse effects of pelvic radiotherapy concern 5 to 10% of them, which could be life threatening. However, a clear medical consensus concerning the clinical management of such healthy tissue sequelae does not exist. Our group has demonstrated in preclinical animal models that systemic MSC injection is a promise approach for the medical management of gastrointestinal disorder after irradiation. We have shown that MSC migrate to damaged tissues and restore gut functions after irradiation. The clinical status of first four patients suffering from severe pelvic side effects resulting from an over-dosage was improved following MSC injection in a compassioned situation. A quantity of 2x106 - 6x106 MSC /kg were infused intravenously to the patients. Pain, hemorrhage, frequency of diarrheas and fistulization as well as the lymphocyte subsets in peripheral blood were evaluated before MSC therapy and during the follow-up. Two patients revealed a substantiated clinical response for pain and hemorrhage after MSC therapy. In one patient pain reappeared after 6 months and again substantially responded on a second MSC infusion. A beginning fistulization process could be stopped in one patient resulting in a stable remission for more than 3 years of follow-up. The frequency of painful diarrhea diminished from an average of 6/d to 3/d after the first and 2/d after the 2nd MSC injection in one patient. In all patients, prostate cancer remained in stable complete remission. A modulation of the lymphocyte subsets towards a regulatory pattern and diminution of activated T cells accompanies the clinical response in refractory irradiation-induced colitis. No toxicity occurred. MSC therapy was safe and effective on pain, diarrhea, hemorrhage, inflammation, fibrosis and limited fistulization. For patients with refractory chronic inflammatory and fistulizing bowel diseases, systemic MSC injections represent a safe option for salvage therapy. A clinical phase II trial will start in 2018.

Alain Chapel has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation, for 25 years. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia), thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. He is Scientific Investigator of clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdominopelvic complications refractory to standard therapy (NCT02814864Hirsch Index 26). His research interests are regenerative medicine, cell therapy, scaffold and radiotherapy.

E-mail: [email protected]